litlas
Log inCreate account

David B. Weiner

Active 1959–2026

177
Papers
24,333
Citations
92
h-index
170
i10-index

Citations

Citations per year for David B. Weiner1964: 1 citations1966: 1 citations1967: 1 citations1976: 1 citations1979: 1 citations1989: 3 citations1990: 23 citations1991: 22 citations1992: 36 citations1993: 41 citations1994: 42 citations1995: 71 citations1996: 55 citations1997: 71 citations1998: 149 citations1999: 190 citations2000: 196 citations2001: 159 citations2002: 121 citations2003: 117 citations2004: 178 citations2005: 126 citations2006: 123 citations2007: 130 citations2008: 159 citations2009: 134 citations2010: 137 citations2011: 148 citations2012: 142 citations2013: 163 citations2014: 159 citations2015: 135 citations2016: 150 citations2017: 140 citations2018: 115 citations2019: 462 citations2020: 824 citations2021: 875 citations2022: 581 citations2023: 485 citations2024: 646 citations2025: 421 citations2026: 7 citations1965: no citations, so this year is not shown1968–1975: no citations, so these years are not shown1977–1978: no citations, so these years are not shown1980–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,619 citing papers, 32.9% of this breakdownChina: 822 citing papers, 10.3% of this breakdownUnited Kingdom: 407 citing papers, 5.1% of this breakdownGermany: 341 citing papers, 4.3% of this breakdownFrance: 319 citing papers, 4% of this breakdownCanada: 271 citing papers, 3.4% of this breakdownIndia: 244 citing papers, 3.1% of this breakdownItaly: 243 citing papers, 3.1% of this breakdownAustralia: 202 citing papers, 2.5% of this breakdownJapan: 201 citing papers, 2.5% of this breakdownNetherlands: 167 citing papers, 2.1% of this breakdownSouth Korea: 143 citing papers, 1.8% of this breakdown
0%32.9%Other 24.9%

Institutions

Fields

  • Medicine43.4%
  • Immunology and Microbiology27.9%
  • Biochemistry, Genetics and Molecular Biology23.9%
  • Agricultural and Biological Sciences1.3%
  • Pharmacology, Toxicology and Pharmaceutics0.9%
  • Engineering0.5%
  • Other2.1%

Topics

  • Immunotherapy and Immune Responses7.3%
  • RNA Interference and Gene Delivery4.7%
  • SARS-CoV-2 and COVID-19 Research4.6%
  • Immune Cell Function and Interaction4.2%
  • HIV Research and Treatment2.8%
  • vaccines and immunoinformatics approaches2.7%
  • Other73.7%

Coauthors

All papers

Open in search
  1. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial

    Authors: Mark Yarchoan, Edward Gane, Thomas U. Marron, Renzo Perales‐Linares, Jian Yan, Neil Cooch, Daniel Shu, Elana J. Fertig, Luciane T. Kagohara, Gábor Bartha, Josette Northcott, John Lyle, Sarah Rochestie, Joann Peters, Jason T. Connor, Elizabeth M. Jaffee, Ildiko Csiki, David B. Weiner, Alfredo Perales‐Puchalt, Niranjan Y. Sardesai - Nature Medicine 2024 cited by 218

  2. Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer

    Authors: Filippo Veglia, Vladimir A. Tyurin, Dariush Mohammadyani, Maria Blasi, Elizabeth K. Duperret, Laxminarasimha Donthireddy, Ayumi Hashimoto, Alexandr A. Kapralov, Andrew A. Amoscato, Roberto Angelini, Sima Patel, Kevin Alicea-Torres, David B. Weiner, Maureen E. Murphy, Judith Klein‐Seetharaman, Esteban Celis, Valerian E. Kagan, Dmitry I. Gabrilovich - Nature Communications 2017 cited by 297

  3. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

    Authors: Cornelia L. Trimble, Matthew P. Morrow, Kimberly A. Kraynyak, Xuefei Shen, Michael Dallas, Jian Yan, Lance Edwards, Raphaëlle Parker, Lynette Denny, Mary Giffear, Ami Shah Brown, Kathleen Marcozzi-Pierce, Divya Shah, Anna M. Slager, Albert J. Sylvester, Amir Sada Khan, Kate E. Broderick, Robert J. Juba, Timothy A. Herring, Jean Boyer, Jessica Lee, Niranjan Y. Sardesai, David B. Weiner, Mark L. Bagarazzi - The Lancet 2015 cited by 714

  4. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy

    Authors: Nils Wellhausen, Ryan P. O’Connell, Stefanie Lesch, Nils W. Engel, Austin K. Rennels, Donna Gonzales, Friederike Herbst, Regina M. Young, K. Christopher García, David B. Weiner, Carl H. June, Saar Gill - Science Translational Medicine 2023 cited by 125

  5. DNA vaccines: ready for prime time?

    Authors: Michele A. Kutzler, David B. Weiner - Nature Reviews Genetics 2008 cited by 1,071

  6. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy

    Authors: Rajasekharan Somasundaram, Thomas Connelly, Robin Choi, Hyeree Choi, Anastasia Samarkina, Ling Li, Elizabeth Gregorio, Yeqing Chen, Rohit Thakur, Mohamed Abdel‐Mohsen, Marilda Beqiri, Meaghan Kiernan, Michela Perego, Fang Wang, Min Xiao, Patricia Brafford, Xue Yang, Xiaowei Xu, Anthony Secreto, Gwenn Danet-Desnoyers, Daniel Traum, Klaus H. Kaestner, Alexander C. Huang, Denitsa M. Hristova, Joshua X. Wang, Mizuho Fukunaga‐Kalabis, Clemens Krepler, Fang Ping-Chen, Xiangyang Zhou, Alexis Gutierrez, Vito W. Rebecca, Prashanthi Vonteddu, Farokh Dotiwala, Shashi Bala, Sonali Majumdar, Harsh Dweep, Jayamanna Wickramasinghe, Andrew V. Kossenkov, Jorge Reyes-Arbujas, Kenisha Santiago, Tran B. Nguyen, Johannes Griss, Frederick Keeney, James E. Hayden, Brian Gavin, David B. Weiner, Luis J. Montaner, Qin Liu, Lukas Peiffer, Jürgen C. Becker, Elizabeth M. Burton, Michael A. Davies, Michael T. Tetzlaff, Kar Muthumani, Jennifer A. Wargo, Dmitry I. Gabrilovich, Meenhard Herlyn - Nature Communications 2021 cited by 184

  7. Engineered transfer RNAs for suppression of premature termination codons

    Authors: John D. Lueck, Jae Seok Yoon, Alfredo Perales‐Puchalt, Adam L. Mackey, Daniel T. Infield, Mark A. Behlke, Marshall R. Pope, David B. Weiner, William R. Skach, Paul B. McCray, Christopher A. Ahern - Nature Communications 2019 cited by 151

  8. DNA vaccines: prime time is now

    Authors: E. Gary, David B. Weiner - Current Opinion in Immunology 2020 cited by 193

  9. Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice

    Authors: Elizabeth K. Duperret, Aspen Trautz, Dylan T. Ammons, Alfredo Perales‐Puchalt, Megan C. Wise, Jian Yan, Charles C. Reed, David B. Weiner - Clinical Cancer Research 2017 cited by 148

  10. Immunogenicity of a DNA vaccine candidate for COVID-19

    Authors: Trevor R.F. Smith, Ami Patel, Stephanie Ramos, Dustin Elwood, Xizhou Zhu, Jian Yan, E. Gary, Susanne N. Walker, Katherine Schultheis, Mansi Purwar, Ziyang Xu, Jewell Walters, Pratik Bhojnagarwala, Maria Yang, Neethu Chokkalingam, Patrick Pezzoli, Elizabeth M. Parzych, Emma L. Reuschel, Arthur Doan, Nicholas J. Tursi, Miguel Vasquez, Jihae Choi, Edgar Tello‐Ruiz, Igor Maricic, Mamadou A. Bah, Yuanhan Wu, Dinah Amante, Daniel H. Park, Yaya Dia, Ali Raza Ali, Faraz I. Zaidi, Alison Generotti, Kevin Y. Kim, Timothy A. Herring, Sophia M. Reeder, Viviane M. Andrade, Karen R. Buttigieg, Gan Zhao, Jiun-Ming Wu, Dan Li, Linlin Bao, Jiangning Liu, Wei Deng, Chuan Qin, Ami Shah Brown, Makan Khoshnejad, Nianshuang Wang, Jacqueline D. Chu, Daniel Wrapp, Jason S. McLellan, Kar Muthumani, Bin Wang, Miles W. Carroll, J. Joseph Kim, Jean Boyer, Daniel W. Kulp, Laurent Humeau, David B. Weiner, Kate E. Broderick - Nature Communications 2020 cited by 640

  11. Innate Lymphoid Cells Promote Anatomical Containment of Lymphoid-Resident Commensal Bacteria

    Authors: Gregory F. Sonnenberg, Laurel A. Monticelli, Theresa Alenghat, Thomas C. Fung, Natalie A. Hutnick, Jun Kunisawa, Naoko Shibata, Stephanie Grunberg, Rohini Sinha, Adam M. Zahm, Mélanie R. Tardif, Taheri Sathaliyawala, Masaru Kubota, Donna L. Färber, Ronald G. Collman, Abraham Shaked, Lynette A. Fouser, David B. Weiner, Philippe A. Tessier, Joshua R. Friedman, Hiroshi Kiyono, Frederic D. Bushman, Kyong‐Mi Chang, David Artis - Science 2012 cited by 725

  12. Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine

    Authors: Pablo Tebas, Christine C. Roberts, Kar Muthumani, Emma L. Reuschel, Sagar B. Kudchodkar, Faraz I. Zaidi, Scott White, Amir S. Khan, Trina Racine, Hyeree Choi, Jean Boyer, Young K. Park, Sylvie Trottier, Celine Remigio, Diane Krieger, Susan E. Spruill, Mark Bagarazzi, Gary P. Kobinger, David B. Weiner, Joel N. Maslow - New England Journal of Medicine 2017 cited by 317

  13. Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers

    Authors: Devivasha Bordoloi, Abhijeet J. Kulkarni, Opeyemi S. Adeniji, M. Betina Pampena, Pratik Bhojnagarwala, Shushu Zhao, Candice Ionescu, Alfredo Perales‐Puchalt, Elizabeth M. Parzych, Xizhou Zhu, Ali Ali, Joel Cassel, Rugang Zhang, Michael R. Betts, Mohamed Abdel‐Mohsen, David B. Weiner - Science Advances 2023 cited by 43

  14. A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge

    Authors: Elizabeth K. Duperret, Alfredo Perales‐Puchalt, Regina Stoltz, Hiranjith G.H., Nitin Mandloi, James L. Barlow, Amitabha Chaudhuri, Niranjan Y. Sardesai, David B. Weiner - Cancer Immunology Research 2019 cited by 109

  15. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors

    Authors: Erwei Song, Pengcheng Zhu, Sang‐Kyung Lee, Dipanjan Chowdhury, Steven Kussman, Derek M. Dykxhoorn, Yi Feng, Deborah Palliser, David B. Weiner, Premlata Shankar, Wayne A. Marasco, Judy Lieberman - Nature Biotechnology 2005 cited by 1,017

  16. Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL

    Authors: Prakash Bhuyan, Michael Dallas, Kim Kraynyak, Timothy A. Herring, Matthew P. Morrow, Jean Boyer, Susan Duff, Joseph Kim, David B. Weiner - Human Vaccines & Immunotherapeutics 2020 cited by 52

  17. Clinical Applications of DNA Vaccines: Current Progress

    Authors: Bernadette Ferraro, Matthew P. Morrow, Natalie A. Hutnick, T. H. Shin, Colleen E. Lucke, David B. Weiner - Clinical Infectious Diseases 2011 cited by 379

  18. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

    Authors: Kayvon Modjarrad, Christine C. Roberts, Kristin T Mills, Amy R. Castellano, Kristopher Paolino, Kar Muthumani, Emma L. Reuschel, Merlin L. Robb, Trina Racine, Myoung‐don Oh, Claude Lamarre, Faraz I. Zaidi, Jean Boyer, Sagar B. Kudchodkar, Moonsup Jeong, Janice M. Darden, Young K. Park, Paul T. Scott, Celine Remigio, Ajay Parikh, Megan C. Wise, Ami Patel, Elizabeth K. Duperret, Kevin Y. Kim, Hyeree Choi, S. M. White, Mark L. Bagarazzi, Jeanine May, Deborah Kane, Hyojin Lee, Gary Kobinger, Nelson L. Michael, David B. Weiner, Stephen J. Thomas, Joel N. Maslow - The Lancet Infectious Diseases 2019 cited by 322

  19. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

    Authors: Pablo Tebas, ShuPing Yang, Jean Boyer, Emma L. Reuschel, Ami Patel, Aaron Christensen-Quick, Viviane M. Andrade, Matthew P. Morrow, Kimberly A. Kraynyak, Joseph Agnes, Mansi Purwar, Albert J. Sylvester, Jan M. Pawlicki, Elisabeth Gillespie, Igor Maricic, Faraz I. Zaidi, Kevin Y. Kim, Yaya Dia, Drew Frase, Patrick Pezzoli, Katherine Schultheis, Trevor R.F. Smith, Stephanie Ramos, Trevor McMullan, Karen R. Buttigieg, Miles W. Carroll, John Ervin, Malissa Diehl, Elliott Blackwood, Mammen P. Mammen, Jessica Lee, Michael Dallas, Ami Shah Brown, Jacqueline E. Shea, J. Joseph Kim, David B. Weiner, Kate E. Broderick, Laurent Humeau - EClinicalMedicine 2020 cited by 282

  20. Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors

    Authors: Robert H. Vonderheide, Kimberly A. Kraynyak, Anthony F. Shields, Autumn J. McRee, Jennifer M. Johnson, Weijing Sun, Ashish V. Chintakuntlawar, Jan M. Pawlicki, Albert J. Sylvester, Trevor McMullan, Robert J. Samuels, Joseph Kim, David B. Weiner, Jean Boyer, Matthew P. Morrow, Laurent Humeau, Jeffrey Skolnik - Journal for ImmunoTherapy of Cancer 2021 cited by 45

  21. Electroporation delivery of DNA vaccines: prospects for success

    Authors: Niranjan Y. Sardesai, David B. Weiner - Current Opinion in Immunology 2011 cited by 418

  22. In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies

    Authors: Ami Patel, Mamadou A. Bah, David B. Weiner - BioDrugs 2020 cited by 69

  23. First Human Trial of a DNA-Based Vaccine for Treatment of Human Immunodeficiency Virus Type 1 Infection: Safety and Host Response

    Authors: Rob Roy MacGregor, Jean Boyer, Kenneth E. Ugen, Katie E. Lacy, Stephen J. Gluckman, Mark L. Bagarazzi, Michael A. Chattergoon, Yaila Baine, Theresa Higgins, Richard B. Ciccarelli, Leslie R. Coney, Richard S. Ginsberg, David B. Weiner - The Journal of Infectious Diseases 1998 cited by 640

  24. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer

    Authors: Charu Aggarwal, Roger B. Cohen, Matthew P. Morrow, Kimberly A. Kraynyak, Albert J. Sylvester, Dawson Knoblock, Joshua Bauml, Gregory S. Weinstein, Alexander Lin, Jean Boyer, Lindsay Sakata, Sophie Seine Xuan Tan, Aubrey Anton, Kelsie Dickerson, Drishty Mangrolia, Russell Vang, Michael Dallas, Sandra Oyola, Susan Duff, Mark T. Esser, Rakesh Kumar, David B. Weiner, Ildiko Csiki, Mark L. Bagarazzi - Clinical Cancer Research 2018 cited by 144